Zacks Investment Research on MSN13d
Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe
Mirum Pharmaceuticals’ MIRM lead product, Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) ...
Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call
Mirum Pharmaceuticals stock surged 25% and how LIVMARLI drives growth. Explore future prospects with Volixibat. Click here to ...
LIVMARLI Now Approved in Japan for ALGS and PFIC
LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and ...
Maintaining An 'Accumulate' Rating On Mirum Pharmaceuticals, Lots To Like
Mirum Pharmaceuticals, Inc. shows strong growth with a 43% revenue jump and promising pipeline assets. Click here for my ...
Mirum Pharmaceuticals partner Takeda receives approval for Livmarli in Japan
Mirum Pharmaceuticals (MIRM) announced that its partner, Takeda (TAK), has received approval by the Japanese Ministry of Health, Labour, and ...
Business Wire1mon
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025
A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults.
Morningstar7d
LIVMARLI Now Approved in Japan for ALGS and PFIC
LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestasis in Japan Mirum Pharmaceuticals ...